Page icon

OUR TEAM

James V. Watson, MA., MB., BS., M.Sc., DMRT., FFR., FRCR.
OnICS Founder, Medical and Software Development Director

Dr. Watson is a Clinical Oncologist who trained initially in Radiotherapy, then in Radiation Biology and has extensive experience in Medical Oncology and Brachytherapy where he developed surgical after-loading techniques for breast and head and neck cancers. In addition, he has considerable computing experience in a variety of languages having started programming when a medical student in 1962. He first embarked on the challenge of developing an electronic medical record and prescribing system in 1968 but his ambitions proved to be impracticable with the computers available to him at that time. He moved from the Middlesex Hospital and London University to Cambridge, UK, in 1975 with appointments as a Senior Clinical Scientist in the Medical Research Council Centre (MRC, including the Laboratory of Molecular Biology) and University of Cambridge, with consultant oncologist contracts in Addenbrooke's and Bedford Hospitals.

Dr. Watson enjoys an international reputation for his work in cytometry and its application in cancer and he designed a dual-laser flow cytometer with 9 detectors at the MRC centre in the late 1970s and early 1980s. He is a past President of the International Society for Analytical Cytology (ISAC) and has lectured in 19 countries in various institutions including NCI and NIH in the USA. He has received three awards, the Edgar Gentilli prize from the Royal College of Obstetrics and Gynaecology, London, UK, the Harold Lupiloff award from Wayne State University, Detroit, USA and the Distinguished Service Award from ISAC.

Dr. Watson has published extensively with over 250 peer reviewed clinical and scientific papers and over 100 abstracts (stopped counting these after 100) in subjects as diverse as optics, statistics, computing (data analysis and multi¨ dimensional data handling and interpretation), clinical medicine, pathology, cell biology, biochemistry and cytometry. He has written three books (two published by Cambridge University Press) and the third, A Guide to Understanding Cancer, will be published on this website.

Dr. Watson founded Medinfomatics Ltd. in 2002 a company dedicated to cancer and health informatics and has developed novel user-friendly digital methods for clinical data capture at point of care. He joined forces with Simon Currey in 2005 and they co-founded OnICS (Oncology Information Capture System) in 2007.

Nathan Hill B.S.c, M.S.c, P.h.D
COO, Product Implementation Director

Dr Hill brings a set of highly complementary computing and clinical software implementation skills to the OnICS team. Dr Hill fulfills a key role in the OnICS team in implentation of the iNOTZ product and is often on location with our reference site customers in Pacific Northwest, Midwest and southern California locations in the USA.

Dr Hillís scientific research started from a very young age in achieving a Darwin Science Award for Young Scientists while studying at Whitchurch High School, Cardiff. Biological studies continued with a B.S.c in Biochemistry where his final year laboratory research was continued for publication after gaining a Wellcome Trust Scholarship. Research focused upon understanding intracellular communication in Heart tissue using digital imaging technologies at the University of Wales, College of Medicine, Cardiff.

A passion for combining biology and computer technology together became apparent during undergraduate study. To attain his goal, Dr Hill refined his computer programming skills with an M.S.c in Computing where his Bioinformatics dissertation focused upon using genetic information to understand cellular processes using complete genomic database information from The European Bioinformatics Institute based in Cambridge.

More recently, application of Dr Hillís computing and biological interests were harnessed in a PhD Studentship at the Tenovus Centre for Cancer Research at the Welsh School of Pharmacy in Cardiff University. His PhD thesis focused upon analysis strategies for novel exploration of in vitro Breast cancer models resistant to successful internationally acclaimed antihormonal therapeutic drugs namely Faslodex and Tamoxifen using Affymetrix Microarray technology. In conjunction with in vitro analysis, the importance of Biomarkers and limitations of certain prognostic indicators was explored using clinical resources such as the Surveillance, Epidemiology, and End Results (SEER) Program dataset from the United States.

Terry Horsnall
Medical and Software Specialist

Dr Horsnell is currently Head of Computing Services at the Laboratory of Molecular Biology in Cambridge, UK. With his expertise in clinical and technological developments, he has had a valuable role in founding OnICS

OnICS Ltd
Tel: +1 253 200 5860
Fax: +44 29 20750239
Email: enquire@onics.co.uk